精神活性物质与神经刺激疗法在大脑重塑中的应用
摘要
斯坦福大学脑刺激实验室主任 Nolan Williams 博士探讨了将transcranial magnetic stimulation（TMS，经颅磁刺激）与迷幻药物相结合的前沿抑郁症治疗方法，涵盖裸盖菇素、氯胺酮、伊博格碱及 MDMA。对话涉及抑郁症的神经回路机制、阿片系统在氯胺酮抗抑郁效果中出人意料的作用，以及新兴的”精神病学 3.0”框架——该框架将抑郁症重新定义为可修复的回路问题，而非化学失衡。Williams 博士实验室的重要研究成果，挑战了长期以来关于 SSRIs 和氯胺酮实际作用机制的既有假设。
核心要点
- 抑郁症是全球最具致残性的疾病之一 —— 目前已被列为冠心病的第四大风险因素，与高血压、高胆固醇和糖尿病并列
- 左侧dorsolateral prefrontal cortex（DLPFC，背外侧前额叶皮质）通过调控前扣带回来管理情绪；在抑郁状态下，这一层级关系发生逆转——前扣带回在时序上先于 DLPFC 激活，而 TMS 可恢复正常秩序
- 氯胺酮的抗抑郁效果主要由阿片系统介导，而非谷氨酸能机制 —— 以 50mg 纳曲酮阻断阿片受体后，氯胺酮的抗抑郁效果显著消除，但解离感并未受影响
- SSRIs 确实有效，但并非通过补充血清素发挥作用 —— “化学失衡”模型已被认为过时；抗抑郁效果可能源于下游Neuroplasticity 神经可塑性（神经可塑性）变化，如BDNF上调
- SAINT（斯坦福加速智能神经调控疗法） 可在 1–5 天内使患者从重度抑郁中缓解，全程采用密集 TMS 治疗，无需任何药物
- DLPFC 与心脏之间的连接是真实且可测量的 —— 刺激左侧 DLPFC 可通过前扣带回 → 脑岛 → 杏仁核 → 孤束核 → 迷走神经这一通路，以时间锁定的方式使心率减慢约 10 次/分钟
- 迷幻药物可能通过Neuroplasticity 神经可塑性发挥作用，而非仅凭主观体验 —— “致幻旅程”本身可能并非主要治疗机制；潜在的药理学特性（如阿片受体活性、BDNF/GDNF 上调）似乎至关重要
- 行为干预，如以呼气为重点的呼吸训练、正念冥想和运动，可能激活相同的 DLPFC-迷走神经回路，但随着抑郁严重程度的增加，其效果会逐渐减弱
- 在高度可塑状态下进行记忆再巩固，可能解释了为何迷幻药物能够化解长期存在的创伤 —— 在迷幻状态下重新体验记忆，会以不同方式完成再巩固
详细笔记
抑郁症：影响范围与生物学机制
- 抑郁症涵盖广泛的症状谱系：快感缺失、焦虑主导型、精神运动迟滞等 —— 基于神经影像学，这些可能代表不同的生物亚型
- 中度抑郁的致残程度大致相当于急性心脏病发作；重度抑郁则与未经治疗的终末期癌症相当
- 抑郁症可使术后第 4 天（如膝关节置换术后）的口服阿片类药物需求量增加三倍，提示抑郁患者对疼痛的感受更为强烈 —— 可能同时涉及躯体和情感层面
- 与心脏病学不同，精神病学随着病情严重程度的增加（从门诊 → 住院 → 急诊），所提供的诊疗工具反而更少，且在最高急性级别时缺乏任何诊断性检测手段
DLPFC–心脏回路
- 通路： 左侧 DLPFC → 前扣带回 → 脑岛 → 杏仁核 → 孤束核 → 迷走神经 → 心脏
- 在 2 秒 TMS 脉冲序列刺激左侧 DLPFC 后，约 1 秒时可观察到心率减慢约 10 次/分钟，与刺激时间精确锁定
- 该效应具有脑区特异性 —— 刺激运动皮质或视觉皮质不会产生此类效应
- 刺激右侧 DLPFC 则导致心率加速，支持半球对情绪的平衡调控：
- 左侧 DLPFC 激活 → 抗抑郁
- 右侧 DLPFC 激活 → 抗躁狂
- 人类连接组计划的数据印证了这一点：导致抑郁的卒中病灶定位于左侧 DLPFC；导致躁狂的病灶定位于右侧 DLPFC
SAINT / 快速 TMS 方案
- 全称： Stanford Accelerated Intelligent Neuromodulation Therapy（SAINT，斯坦福加速智能神经调控疗法，又称 SNT）
- 密集刺激方案在连续 5 天内完成
- 靶点为左侧 DLPFC 中与膝下前扣带回（情绪处理脑区）功能连接最强的区域
- 疗效：患者在 1–5 天内实现完全缓解（抑郁量表评分降至零）
- 在治疗应答者中，神经影像学显示 DLPFC 重新获得相对于前扣带回的时序优先性 —— 恢复健康大脑的正常激活时序
- 部分提前缓解的患者在治疗周结束时，自发报告出现类似正念的当下觉察状态 —— 这是一项尚未发表的轶事性发现
氯胺酮与阿片系统
- 普遍认知：氯胺酮通过 NMDA 受体拮抗（谷氨酸系统）发挥作用
- 关键研究： 在标准治疗性氯胺酮输注前给予 50mg 纳曲酮（阿片受体阻断剂），显著阻断了抗抑郁效果 —— 但不影响解离感
- 这表明阿片系统对氯胺酮的抗抑郁作用是必要条件（但非充分条件）
- 长期使用阿片类药物尽管具有急性抗抑郁样效果，但从长远来看似乎会促进抑郁的发生
- 另外，TMS 介导的镇痛效果同样可被静脉注射纳洛酮所阻断，提示脑刺激与药物治疗之间可能存在共同的阿片介导机制
SSRIs 与”化学失衡”模型
- SSRIs 对抑郁症、强迫症、广泛性焦虑障碍和恐慌症确实有效 —— 已获多项 meta 分析证实
- 然而，其延迟起效的特点（数天至数周）提示血清素再摄取阻断本身并非直接驱动因素
- 更可能的机制：下游神经可塑性效应，包括BDNF上调
- “化学失衡/血清素缺乏”模型在精神病学领域已被认为在科学上过时 —— 尽管直到近期媒体报道之前，这一认知并未被广泛传达给公众
- TMS 在完全不改变血清素水平的情况下即可获得同等甚至更快的抗抑郁效果，进一步动摇了以血清素为核心的模型
精神病学 3.0 框架
- 精神病学 1.0： 心理治疗/精神分析 —— 聚焦于早期经历与心理动力学
- 精神病学 2.0： 药物治疗/化学失衡 —— 聚焦于神经递质的纠正
- 精神病学 3.0： 回路导向 —— 聚焦于运用神经调控手段或神经可塑性诱导药物，重新校准失调的大脑网络
- 核心转变：抑郁症被重新定义为可恢复的回路问题，而非永久性缺陷 —— 赋予患者自主感，并让其认识到缓解是可以实现的
迷幻药物：机制与临床应用
- 裸盖菇素、MDMA、伊博格碱、DMT、氯胺酮和大麻均在斯坦福大学脑刺激实验室的研究范围之内
- 神经影像学显示，裸盖菇素和氯胺酮使用后，膝下前扣带回/默认模式网络出现持久的回路层面变化 —— 与 TMS 所影响的脑区相同 —— 且在药物清除后仍持续存在
- 在迷幻状态下进行记忆再巩固，可能解释了 PTSD 症状的长期缓解 —— 在高度神经可塑状态下重新体验创伤，使其以不同方式完成再巩固
- 伊博格碱及其他迷幻药物可上调BDNF和GDNF，促进神经可塑性
- 当前研究热点：迷幻药物的非致幻类似物能否保留抗抑郁效果？动物实验数据（LSD 类似物）提示可能可以；人类数据尚待明确
- 主观”致幻旅程”可能并非主要机制 —— 独立于心理体验之外的药理学特性似乎至关重要
行为干预与阈值效应
- Breathwork（以呼气为重点或慢节奏呼吸训练）、冥想和运动可能激活 DLPFC-迷走神经回路，从而缓解**
English Original 英文原文
Psychedelics & Neurostimulation for Brain Rewiring
Summary
Dr. Nolan Williams, director of Stanford’s Brain Stimulation Lab, discusses cutting-edge treatments for depression combining transcranial magnetic stimulation (TMS) with psychedelics including psilocybin, ketamine, ibogaine, and MDMA. The conversation covers the neural circuitry of depression, the surprising role of the opioid system in ketamine’s antidepressant effects, and the emerging “Psychiatry 3.0” framework that reframes depression as a fixable circuit problem rather than a chemical imbalance. Key research from Dr. Williams’ lab challenges long-held assumptions about how both SSRIs and ketamine actually work.
Key Takeaways
- Depression is the most disabling condition worldwide — now listed as the 4th major risk factor for coronary artery disease alongside hypertension, high cholesterol, and diabetes
- The left dorsolateral prefrontal cortex (DLPFC) governs mood by regulating the anterior cingulate; in depression, this hierarchy is inverted — the cingulate precedes the DLPFC in timing, and TMS can restore normal order
- Ketamine’s antidepressant effect is largely opioid-mediated, not glutamatergic — blocking opioid receptors with 50mg naltrexone dramatically eliminated ketamine’s antidepressant effect without affecting dissociation
- SSRIs work, but not through serotonin replenishment — the “chemical imbalance” model is considered outdated; antidepressant effects likely arise from downstream Neuroplasticity 神经可塑性 changes such as BDNF upregulation
- SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) can bring people out of severe depression in 1–5 days using intensive TMS without any pharmacology
- The DLPFC-heart connection is real and measurable — stimulating the left DLPFC decelerates heart rate ~10 BPM in a time-locked manner via a tract through the anterior cingulate → insula → amygdala → nucleus tractus solitarius → vagus nerve
- Psychedelics may work through Neuroplasticity 神经可塑性, not just the subjective experience — the “trip” may not be the primary therapeutic mechanism; underlying pharmacology (e.g., opioid receptor activity, BDNF/GDNF upregulation) appears essential
- Behavioral interventions like exhale-emphasized breathing, mindfulness, and exercise may access the same DLPFC-vagal circuit, though they lose efficacy as depression severity increases
- Memory reconsolidation in a highly plastic state may explain why psychedelics resolve long-standing trauma — re-experiencing a memory under psychedelics reconsolidates it differently
Detailed Notes
Depression: Scope and Biology
- Depression encompasses a wide spectrum: anhedonia, anxiety-dominant, psychomotor retardation, and more — likely representing distinct biotypes based on neuroimaging
- Moderate depression is roughly as disabling as an acute heart attack; severe depression is comparable to untreated terminal cancer
- Depression triples oral opioid requirements by day 4 post-surgery (e.g., knee replacement), suggesting depressed patients experience greater pain — likely both physical and emotional
- Unlike cardiology, psychiatry provides fewer tools as acuity increases (from outpatient → inpatient → emergency), with no diagnostic tests at the highest acuity levels
The DLPFC–Heart Circuit
- Pathway: Left DLPFC → anterior cingulate → insula → amygdala → nucleus tractus solitarius → vagus nerve → heart
- Stimulating the left DLPFC during a 2-second TMS train produces ~10 BPM heart rate deceleration at 1 second, time-locked to stimulation
- This effect is region-specific — stimulating motor or visual cortex produces no such effect
- Stimulating the right DLPFC produces acceleration, supporting hemispheric balancing of mood:
- Left DLPFC excitation → antidepressant
- Right DLPFC excitation → anti-manic
- This is confirmed by the Human Connectome Project: stroke lesions causing depression map to left DLPFC; lesions causing mania map to right DLPFC
SAINT / Rapid TMS Protocol
- Full name: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT or SNT)
- Dense stimulation delivered over 5 consecutive days
- Targets the portion of the left DLPFC functionally connected to the subgenual anterior cingulate (emotion-processing region)
- Results: Patients achieve full remission (zeroed-out depression scales) within 1–5 days
- In treatment-responders, neuroimaging shows the DLPFC regains temporal precedence over the anterior cingulate — restoring the normal healthy brain timing pattern
- Some patients who remit early report spontaneous mindfulness-like states of present-moment awareness by the end of the week — an unreported anecdotal finding
Ketamine and the Opioid System
- Common assumption: ketamine works via NMDA receptor antagonism (glutamate system)
- Key study: 50mg naltrexone (opioid receptor blocker) given before a standard therapeutic ketamine infusion dramatically blocked the antidepressant effect — without altering dissociation
- This suggests the opioid system is necessary (though not sufficient) for ketamine’s antidepressant action
- Chronic opioid use appears pro-depressant over time despite acute antidepressant-like effects
- Separately, TMS-mediated pain relief was also blocked by IV naloxone, suggesting a shared opioid-mediated mechanism across brain stimulation and pharmacology
SSRIs and the “Chemical Imbalance” Model
- SSRIs are effective for depression, OCD, GAD, and panic — confirmed by many meta-analyses
- However, the delayed onset (days to weeks) suggests serotonin reuptake blockage itself isn’t the direct driver
- More likely mechanism: downstream neuroplasticity effects, including BDNF upregulation
- The “chemical imbalance / serotonin deficiency” model is considered scientifically outdated within psychiatry — though this was not widely communicated to the public until recent media coverage
- TMS achieves equivalent or faster antidepressant effects without altering serotonin at all, further undermining the serotonin-centric model
Psychiatry 3.0 Framework
- Psychiatry 1.0: Psychotherapy / psychoanalysis — focus on early experience and psychodynamics
- Psychiatry 2.0: Pharmacology / chemical imbalance — focus on neurotransmitter correction
- Psychiatry 3.0: Circuit-based — focus on recalibrating dysfunctional brain networks using neuromodulation or neuroplasticity-inducing compounds
- Key shift: Depression reframed as a recoverable circuit problem, not a permanent deficit — empowering patients with a sense of agency and the knowledge that remission is achievable
Psychedelics: Mechanism and Clinical Applications
- Psilocybin, MDMA, ibogaine, DMT, ketamine, and cannabis are all under study at Stanford’s Brain Stimulation Lab
- Neuroimaging shows lasting circuit-level changes in the subgenual/default mode network after psilocybin and ketamine — in the same regions affected by TMS — persisting long after the drug clears
- Memory reconsolidation under psychedelics may explain long-term resolution of PTSD symptoms — re-experiencing trauma in a highly neuroplastic state allows different reconsolidation
- Ibogaine and other psychedelics upregulate BDNF and GDNF, promoting neuroplasticity
- Active research question: Can non-hallucinogenic analogs of psychedelics retain antidepressant effects? Animal data (LSD analog) suggests possibly yes; human data pending
- The subjective “trip” may not be the primary mechanism — pharmacological properties independent of the psychological experience appear critical
Behavioral Interventions and Thresholds
- Breathwork (exhale-emphasized or slow cadence breathing), meditation, and exercise may access the DLPFC-vagal circuit and alleviate **